CYG-N-2278

CYG-N-2278 is a potent and selective small molecule inhibitor of G protein-coupled receptor kinase 2 (GRK2), originally developed by Cygnal Therapeutics for oncology applications. GRK2 is a serine-threonine kinase that plays a critical role in the phosphorylation and desensitization of G protein-coupled receptors (GPCRs), as well as in non-GPCR signaling pathways. CYG-N-2278 exerts its anti-tumor effects through a dual mechanism: it directly inhibits cancer cell proliferation by slowing G2/M cell cycle progression and indirectly promotes anti-tumor immunity by upregulating proinflammatory cytokine expression in myeloid cells. Preclinical studies have demonstrated significant tumor growth inhibition in pancreatic cancer patient-derived xenograft (PDX) models and syngeneic colorectal cancer models, particularly in immunocompetent settings, suggesting an immune-mediated component to its efficacy.